A new trial of an Alzheimer's drug will test whether it can prevent the onset of the disease in people who are genetically predisposed to get it. If the drug is successful, there is hope -- but no guarantee -- that it could prevent Alzheimer's among the general public. We discuss the trial and its possible implications.
Geoffrey Kerchner, assistant professor of neurology at the Stanford School of Medicine
Eric Reiman, CEO of Banner Research and executive director of Banner Alzheimer's Institute, a nonprofit dedicated to preventing Alzheimer's that is one of the study's leaders
William Fisher, CEO of the Alzheimer's Association of Northern California and Northern Nevada